IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis ; volume:10 ; number:1 ; day:24 ; month:12 ; year:2021 ; pages:1-4 ; date:12.2021
Experimental hematology & oncology ; 10, Heft 1 (24.12.2021), 1-4, 12.2021
- Urheber
-
Cumbo, Cosimo
Tarantini, Francesco
Anelli, Luisa
Zagaria, Antonella
Redavid, Immacolata
Minervini, Crescenzio Francesco
Coccaro, Nicoletta
Tota, Giuseppina
Ricco, Alessandra
Parciante, Elisa
Conserva, Maria Rosa
Specchia, Giorgina
Musto, Pellegrino
Albano, Francesco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-021-00253-y
- URN
-
urn:nbn:de:101:1-2022041621061092281818
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cumbo, Cosimo
- Tarantini, Francesco
- Anelli, Luisa
- Zagaria, Antonella
- Redavid, Immacolata
- Minervini, Crescenzio Francesco
- Coccaro, Nicoletta
- Tota, Giuseppina
- Ricco, Alessandra
- Parciante, Elisa
- Conserva, Maria Rosa
- Specchia, Giorgina
- Musto, Pellegrino
- Albano, Francesco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Targeted therapies for myeloproliferative neoplasms
Esophageal lesions in myeloproliferative neoplasms
Novel therapeutics in myeloproliferative neoplasms
C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
New mouse models of myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Targeted therapies for myeloproliferative neoplasms
Esophageal lesions in myeloproliferative neoplasms
Novel therapeutics in myeloproliferative neoplasms
C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
New mouse models of myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
Targeted therapies for myeloproliferative neoplasms
Esophageal lesions in myeloproliferative neoplasms
Novel therapeutics in myeloproliferative neoplasms
C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms